RTP Mobile Logo

Complete Response Rates with Lenalidomide/Rituximab in the Front-Line Treatment of Indolent B-Cell Non-Hodgkin Lymphoma (NHL)

In Vivo Purging with Rituximab Before Stem Cell Collection and Maintenance Rituximab After Transplant for Patients with Relapsed Follicular Lymphoma (FL)

Maintenance Rituximab for Patients with Follicular Lymphoma (FL) Responding to Front-Line Induction with Rituximab/Chemotherapy

HR Form | Publishing/Production Traffic Administrator Resume Submission Form

Please take a moment for fill out the attached questionnaire before submitting your resume and/or cover letter.

5-Minute Journal Club — ASCO 2010 Presentations

5-Minute Journal Club — ASCO 2010 Presentations

B-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid Tumors

Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases

Ipilimumab or the gp100 Vaccine or the Combination of Both as Therapy for Patients with Metastatic Melanoma

5-Minute Journal Club — ASCO 2010 Presentations

5-Minute Journal Club — ASCO 2010 Presentations

Bevacizumab in the Primary Treatment of Advanced Ovarian, Peritoneal or Fallopian Tube Carcinoma

AMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube Carcinoma

Correlation of BRCA Mutation Status with Responses to Platinum Therapy and PARP Inhibitors in Patients with Ovarian Cancer and Triple-Negative Breast Cancer (TNBC)

Bevacizumab in the Primary Treatment of Advanced Ovarian, Peritoneal or Fallopian Tube Carcinoma

5MJC Multimumor A

Pellentesque urna enim, mattis nec rhoncus eget, pharetra mattis quam. Phasellus nibh nibh, aliquet sit amet molestie eget